A Phase 3 interventional study of PharmaNord Bio-Quinone Active CoQ10 Gold 100mg and PharmaNord Placebo in Gulf War Syndrome, Persian Gulf Syndrome and Mitochondrial Disorder, Respiratory Chain, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of California, San Diego · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Persian Gulf Syndrome with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Persian Gulf Syndrome · United States.
Among the 41 studies in Persian Gulf Syndrome with a site in United States, this one is the 4th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 38th registered.
41 studies on the registry are indexed under Persian Gulf Syndrome; 9 are open to participants now.
Browse Persian Gulf Syndrome studies →9 of the 41 studies in Persian Gulf Syndrome with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 40–80
Baylor College of Medicine · Sites in United States
Ages 50–70
VA Office of Research and Development · Sites in United States
Ages 50–85
Baylor College of Medicine · Sites in United States
Ages 18–64
Nova Southeastern University · Sites in United States
Ages 47–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Persian Gulf Syndrome studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 5
First in 1999; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 54 across 30 interventional studies indexed under Persian Gulf Syndrome.
Median enrollment 53 across the 31 interventional studies, 50 across the 7 observational. Of the 27 that completed or were terminated, 10 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 41 have an industry lead sponsor. The 10 most frequent:
University of California, San Diego is the lead sponsor of 980 studies on the registry; 194 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
University of California, San Diego has 2 studies filed under Persian Gulf Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Persian Gulf Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
| NCT05820893VA Office of Research and DevelopmentResistant Potato Starch to Alleviate GWI | 2027-06-30 |
| NCT07266571University of Alabama at BirminghamPycnogenol (French Maritime Pine Bark) for the Treatment of Gulf War Illness | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 41 studies in Persian Gulf Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PharmaNord Ubiquinone 100mg/1x day
Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
PharmaNord Ubiquinone 100mg/3x day
Drug: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Placebo (made by PharmaNord, matches active treatment)
Drug: PharmaNord Placebo
Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.
Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.
Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.
Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. on placebo.
All outcomes are assessed as change from baseline.
Time frame: 3.5 months
Percent improved on timed chair rises from Gulf War Illness Modified Lower Extremity Summary Performance Score.
All outcomes are assessed as change from baseline.
Time frame: 3.5 months
Mean change in single-item General Self-Rated Health (GSRH).
All outcomes are assessed as change from baseline. 5 point scale, higher is good.
Time frame: 3.5 months
Individual GWI Symptoms
7 validated single-item symptom self-ratings: headache; energy; fatigue with exertion, muscle pain; irritability; impatience; trouble recalling words/names. Each benefited with coQ10, p\<0.05 (two-sided), in the prior coQ10 trial.
Time frame: 3.5, 7 months
Relation of change in time to do five chair rises to change in blood level of coenzyme Q10
Benefit to timed chair rises will relate to blood coQ10 change. This outcome assesses the relation between change in time to complete five chair rises (in seconds) to change in blood level of CoQ10 (in ug/mL). The prediction of change in time to perform five chair rises by change in coQ10 blood level (regression with robust standard errors).
Time frame: 3.5, 7 months
Effect of CoQ10 in the majority male subset on symptoms.
Change in symptoms on coQ10 versus placebo will be assessed in men (male subset of sample).
Time frame: 3.5, 7 months
Effect of CoQ10 in the majority male subset on timed chair rises.
Change in timed chair rises on coQ10 versus placebo will be assessed in men (male subset of sample).
Time frame: 3.5, 7 months
Effect of CoQ10 in the majority male subset on GSRH.
Change in GSRH on coQ10 versus placebo will be assessed in men (male subset of sample).
Time frame: 3.5, 7 months
The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on symptoms.
Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on symptoms.
Time frame: 3.5, 7 months
The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on timed chair rises.
Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on timed chair rises.
Time frame: 3.5, 7 months
The investigator will assess whether there is a difference in change effect for the 100mg/day vs 300mg/day arm on GSRH.
Compare the effect of coQ10 300mg/day to placebo, and to coQ10 100mg/d on GSRH.
Time frame: 3.5, 7 months
Duration Effect on symptoms. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on symptoms.
Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months).
Time frame: 7 months
Duration Effect on timed chair rises. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on timed chair rises.
Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months).
Time frame: 7 months
Duration Effect on GSRH. Compare effects of 7 months vs 3.5 months of treatment, assessed at the same time point after baseline (7 months) on GSRH.
Following seven months of study participation, participants will have been on coQ10 for either 3.5 months or 7 months. These two groups will be compared to assess the impact of longer vs. shorter duration treatment (those initially randomized to placebo will crossover to active coQ10 for the final 3.5 months, while those originally randomized to coQ10 will have been on coQ10 for 7 months).
Time frame: 7 months
Blood Pressure
Specifically, change in blood pressure on coq10 versus placebo will be assessed considering those with low blood pressure at baseline separately from those with borderline or high blood pressure at baseline.
Time frame: 3.5, 7 months
Mitochondrial Function from blood spot card. Maximal respiration will be assessed by the "adopted transfer" technique.
Time frame: 3.5, 7 months
Mitochondrial Function from blood spot card. Spare capacity will be assessed by the "adopted transfer" technique.
Time frame: 3.5, 7 months
Inflammation (hsCRP) will be assessed as change from baseline and compared on active treatment vs. placebo.
Time frame: 3.5, 7 months
Oxidative Stress
Time frame: 3.5, 7 months
Liver Function. Alanine aminotransferase and aspartate aminotransferase will be assessed as change from baseline and compared on active treatment vs. placebo.
Time frame: 3.5, 7 months
Dropouts for Cause. The investigator will report participants who drop out for a reason.
For instance, participants who transition from coQ10 to placebo might drop because of lost of needed benefits of coQ10 -- because the participant felt worse. Alternatively, participants who transition from placebo run-in to coQ10 might drop out due to problems like activation insomnia on active treatment. The number of dropouts will be compared on active treatment vs placebo, and the causes of dropout will be compared also. (Participants who drop because their physicians ask them to do so for some unrelated reason, not because the patient has had a problem or perceive a problem, will count as dropouts, but not as dropouts for "cause" -- cause here refers to a symptom change and/or medical event.) In addition to overall assessment, assessment of dropouts for cause will be evaluated stratified by whether the participant is transitioning from coQ10.
Time frame: 3.5, 7 months
Relation of change in symptoms to change in blood level of coenzyme Q10
This outcome assesses the relation between change in symptoms to change in blood level of CoQ10 (in ug/mL).
Time frame: 3.5 +/- 0.5 months (priority), and ~7 months
Relation of change in single-item General Self-Rated Health (GSRH) to change in blood level of coenzyme Q10
This outcome assesses the relation between change in single-item General Self-Rated Health (GSRH) to change in blood level of CoQ10 (in ug/mL). The GSRH is a 5 point scale, higher is good.
Time frame: 3.5, 7 months
Subset effects in those citing prior coQ10 use, stratified by whether benefit had been perceived.
Time frame: 3.5, 7 months
Analysis stratified by presence of symptoms compatible with sleep apnea
For inclusion in sleep apnea stratum during analysis, the following will be qualifying: Diagnosed sleep apnea, nocturia, awaking from sleep gasping or choking (or observed by others gasping or choking during sleep), daytime hypersomnolence, night sweats, or awaking with headache or anxiety. This is exploratory, but each outcome will be stratified by sleep apnea-compatible problems.
Time frame: 3.5, 7 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Diego →